Antiretroviral toxicity and oxidative stress

American Journal of Pharmacology and Toxicology

Volumn 8, Issue 4, 2013, Pages 187-196

  Elias, Adikwu ^a   Nelson, Brambaifa ^a   Oputiri, Deo ^b   Geoffrey, Oru Bo Precious ^b  

^a UNIVERSITY OF PORT HARCOURT   (Nigeria)

^b Ogbia   (Nigeria)

Author keywords

Antioxidants; Antiretroviral; Oxidative radicals; Oxidative stress; Toxicity

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABNORMAL DREAMING; ALLERGIC REACTION; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CONCENTRATION LOSS; DIABETES MELLITUS; DIARRHEA; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDERMOLYSIS; EXPERIMENTAL ANIMAL; HALLUCINATION; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATOLOGIC DISEASE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INSOMNIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPID PEROXIDATION; LIVER TOXICITY; MENTAL DISEASE; MENTAL INSTABILITY; METABOLIC DISORDER; MITOCHONDRIAL DNA DISORDER; MYOPATHY; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PANCREATITIS; PERIPHERAL NEUROPATHY; PROTEIN DEPLETION; PSYCHOPATHY; RADICAL REACTION; RASH; REDOX STRESS; STEVENS JOHNSON SYNDROME; TOXICITY TESTING; TOXICOKINETICS; TOXICOLOGY;

EID: 84892408601     PISSN: 15574962     EISSN: 15574970     Source Type: Journal    
DOI: 10.3844/ajptsp.2013.187.196     Document Type: Article

References (87)

1. Aberg, J.A., J.E. Kaplan and H. Libman, 2009. Primary care guidelines for the management of persons infected with human immunodeficiency virus: Update by the HIV medicine association of the infectious diseases society of america. Clin. Infect. Dis., 49: 651-681. DOI: 10.1086/605292
2. Abrescia, P. and P. Golino, 2005. Free radicals and antioxidants in cardiovascular diseases. Expert Rev. Cardiovasc Ther., 3: 159-171. DOI: 10.1586/14779072.3.1.159
3. Adjene, J.O., J.A. Avbunudiogba and P.S. Igbigbi, 2011. Oxidative stress induced by chronic administration of efavirenz on the intracranial visual relay centers of adult wistar rats. Biol. Med., 3: 16-24.
4. Apostolova, N., L.J. Gomez-Sucerquia, A. Moran, A. Alvarez and A Blas-Garcia at al., 2010. Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells. Br. J. Pharmacol., 160: 2069-2084. DOI: 10.1111/j.1476-5381.2010.00866.x
5. Atiba, A.S., D.P. Oparinde, A.K. Jimoh, O.A. Babatunde and A. Adelekan et al., 2012. Oxidative stress and serum selenium in HIV patients on different antiretroviral regimen. Greener J. Med. Sci., 2: 163-167.
6. Baliga, R.S., C. Liu, D.G. Hoyt, A.A. Chaves and J.A. Bauer, 2004. Vascular endothelial toxicity induced by HIV protease inhibitor. Cardiovasc. Toxicol., 2: 199-206. DOI: 10.1385/CT:4:2:199
7. Barre-Sinoussi, F., J.C. Chermann, F. Rey, M.T. Nugeyre and S. Chamaret at al., 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for Acquired Immune Deficiency Syndrome (AIDS). Science, 220: 868-871. PMID: 6189183
8. Ben-Romano, R., A. Rudich, S. Etzion, R. Potashnik and E. Potashnik et al., 2006. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: Differential protective effect of antioxidant agents. Antivir. Ther., 11: 1051-1060. PMID: 17302375
9. Bera, E., D. Naidoo and M. Williams, 2012. Maternal deaths following nevirapine-based antiretroviral therapy. South Afr. J. HIV Med., 13: 196-197. DOI: 10.7196/sajhivmed.869
10. Chandra, S., D. Mondal and K.C. Agrawal, 2009. HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: Protection with thymoquinone, experim. Biol. Med., 234: 442-453. DOI: 10.3181/0811-RM-317
11. Cho, H.Y., S. Thomas, E.B. Golden, K.J. Gaffney and F.M. Hofman et al., 2009. Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. Cancer Lett., 282: 87-97. DOI: 10.1016/j.canlet.2009.03.007, PMID: 19345476
12. Cooper, D., J. Heera, J. Goodrich, M. Tawadrous and M. Saag et al., 2010. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection. J. Infec. Dis., 201: 803-813. DOI: 10.1086/650697
13. Cossarizza, A. and G. Moyle, 2004. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS, 18: 137-151. PMID: 15075530
14. Day, B.J. and W. Lewis, 2004. Oxidative stress in NRTIinduced toxicity: Evidence from clinical experience and experiments in vitro and in vivo. Cardiovascular Toxicol., 4: 207-216. PMID: 15470269
15. De Clercq, E., 2009. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents, 33: 307-320. PMID: 19108994
16. Djedaini, M., P. Peraldi, M.D. Drici, C. Darini and P. Saint-Marc et al., 2009. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem. Biophy. Res. Commun., 386: 96-100. DOI: 10.1016/j.bbrc.2009.05.14
17. Domingo, P. and F. Lozano, 2011. Management of antiretroviral drug toxicity. Enfermedades Infecciosas Mic. Clin., 29: 535-544. DOI: 10.1097/01.COH.0000239856
18. Elias, A. and N. Brambaifa, 2013. Concentration-effect, incidence and mechanism of nevirapine hepatotoxicity. Am. J. Pharmacol. Toxicol., 8: 20-30. DOI: 10.3844/ajptsp.2013.20.30
19. Elias, A., O. Deo, O.B.P. Geoffrey and D.A. Enimeya, 2013. Nevirapine hepatotoxicity: Implications of risk factors. Am. J. Pharm. Toxicol., 8: 51-63. DOI: 10.3844/ajptsp.2013.51.63
20. Elsayed, R.K. and D.J. Caldwell, 2010. Etravirine a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection. Am. J. Health. Syst. Pharm., 67: 193-205. DOI: 10.2146/ajhp080559
21. Emery, S. and A. Winston, 2009. Raltegravir: A new choice in HIV and new chance for research. Lancet, 374: 764-766. DOI: 10.1016/S0140-6736, PMID: 19647865
22. Eron, J.J., B. Young, A. Cooper, M. Youle and P. Sklar et al., 2010. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet, 375: 396-407. DOI: 10.1016/S0140-6736(09)62041-9
23. Ferraresi, R., L. Troiano, E. Roat, E. Nemes and E. Lugli et al., 2006. Protective effect of acetyl-L-carnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett., 580: 6612-6616. DOI: 10.1016/j.febslet.2006.11.016
24. Gallant, J.E. and S. Deresinski, 2003. Tenofovir disoproxil fumarate. Clin. Infec. Dis., 37: 944-950. DOI: 10.1086/378068
25. Gerschenson, M. and K. Brinkman, 2004. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion, 4: 763-777. DOI: 10.1086/605292
26. Gil, L., A. Tarinas, D. Hernadez, B.V. Riveron and D. Perez et al., 2010. WITHDRAWN: Altered oxidative stress indexes related to disease progression marker in human immunodeficiency virus infected patients with antiretroviral therapy. Biomed. Pharmacother. PMID: 20951539
27. Glesby, D.R., 2002. Overview of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors.
28. Guo, Y. and H.B. Fung, 2004. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. Pharmacotherapy, 24: 1089-1094. PMID: 15338857
29. Hassan, A., A.A. Babadoko, A.I. Mamman and S.A. Ahmed, 2009. Zidovudine induced pure red cell aplasia: A case report. Niger J. Med.,18: 332-333. PMID: 20120657
30. Havlir, D.V., 2008. HIV integrase inhibitors. out of the pipeline and into the clinic. N. Engl. J. Med., 359: 416-418. DOI: 10.1056/NEJMe0804289
31. Hill, A., W. Sawyer and B. Gazzard, 2009. Effects of first-line use of nucleoside analogues: Efavirenz and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin. Trials., 10: L1-S12. PMID: 19362991
32. Huang, J., L. Meixner, S. Fernandez and J.A. McCutchan, 2009. A double-blinded, randomized controlled trial of zoledronate therapy for HIVassociated osteopenia and osteoporosis. AIDS, 23: 51-57. DOI: 0.1097/QAD.0b013e32831c8adc
33. Hughes, P.J., E. Cretton-Scott, A. Teague and T.M. Wensel, 2011. Protease inhibitors for patients with HIV-1 infection: A comparative overview. P T., 36: 332-345. PMID: 21785550
34. Hulgan, T., J.D. Morrow, R.T. D'Aquila, S. Raffanti and M. Morgan et al., 2003. Oxidant stress is increasing during treatment of human immunodeficiency virus infection. Clin. Infect. Dis., 37: 1711-1717. PMID: 14689356
35. Hurwitz, B.E., J.R. Klaus, M.M. Llabre, A. Gonzalez and P.J. Lawrence et al., 2007. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation. Arch. Intern. Med., 167: 148-154. DOI: 10.1001/archinternmed.2012.2706
36. James, C.L.P., P. Lee and M. Sweet, 2012. Rilpivirine: A second-generation nonnucleoside reverse transcriptase inhibitor. Am. J. Health-Syst. Pharm., 69: 857-861. DOI: 10.2146/ajhp110395
37. Jena, A., R.K. Sachdeva, A. Sharma and A. Wanchu, 2009. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: A 24-week prospective Study. J. Int. Assoc. Providers of AIDS Care, 8: 318-322. DOI: 10.1177/1545109709343967
38. Jiang, B., V.Y. Hebert A.R. Khandelwal K.Y. Stokes and T.R. Dugas, 2009. HIV-1 antiretrovirals induce oxidant injury and increase intimamedia thickness in an atherogenic mouse model. Toxicol. Lett., 187: 164-171. DOI: 10.1016/j.toxlet.2009.02.017
39. Jiang, B., V.Y. Hebert, Y. Li, J.M. Mathis and J.S. Alexander et al., 2007. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol. Applied Pharmacol., 224: 60-71. DOI: 1016/j.taap.2007.06.010
40. Kaferle, J. and C.E. Strzoda, 2009. Evaluation of macrocytosis. Am. Fam. Phys., 1: 203-208.
41. Kashou, A.H. and A. Agarwal, 2011. Oxidants and antioxidants in the pathogenesis of HIV/AIDS. Open Reproductive Sci. J., 3: 154-161. DOI: 10.2174/1874255601103010154
42. Katlama, L.P., R. Haubrich and J. Lalezaric, 2009. Efficacy and safety of etravirine in treatment experienced, HIV-1 patients: Pooled 48-week analysis of two randomized, controlled trials. AIDS, 23: 2289-2300. DOI: 10.1097/QAD.0b013e3283316a5e
43. Kohler, J.J., S.H. Hosseini, A. Hoying-Brandt, E. Green and D.M. Johnson et al., 2009. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Laboratory Investigat., 89: 513-519. DOI: 10.1038/labinvest.2009.14
44. Krambovitis, E., F. Porichis and D.A. Spandidos, 2005. HIV entry inhibitors: A new generation of antiretroviral drugs. Acta Pharmacol. Sin., 26: 1165-73. DOI: 10.1111/j.1745-7254.2005.00193.x
45. Lauderback, C.M., J. Drake, D. Zhou, J.M. Hackett and A. Castegna et al., 2003. Derivatives of xanthic acid are novel antioxidants: Application to synaptosomes. Free Radic. Res., 37: 355-365. DOI: 10.1080/1071576021000040664
46. Lennox, J.L., E. DeJesus and A.A. Lazzarin, 2009. STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet, 374: 796-806. DOI: 10.1016/S0140-6736(09)60918-1
47. Lewis, W., 2003. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: Experimental clarifications and persistent clinical questions. Anti. Res., 58: 189-197. PMID: 12767466
48. Lundgren, J., P. Reiss and S. Worm, 2009. Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI and NRTI drug classes: the D:A:D study. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Feb. 8-11, Alexandria, VA, USA., pp: 318-330. DOI: 10.1086/649897
49. Madruga, J.V., P. Cahn, B. Grinztejn, R. Haubrich and J. Lalezari et al., 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370: 29-38. PMID: 17617271
50. Manda, K.R.A.B., W.A. Banks and N. Ercal, 2011. Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Free Radical Biol. Med., 50: 801-810. DOI: 1016/j.freeradbiomed.2010.12.029
51. Mandas, A., E.L. Lorio, M.G. Congiu, C. Balestrieri and A. Mereu et al., 2009. Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. J. Biomed. Biotechnol., 18: 67-79. DOI: 10.1155/2009/749575
52. Masia, M., S. Padilla, E. Bernal, M.V. Almenar and J. Molina et al., 2007. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: A prospective cross-sectional study in HIV-infected patients. Clin. Therap., 29: 448-455. DOI: 10.1016/j.clinthera.2007.07.025
53. Meanwell, N.A. and J.F. Kadow, 2007. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr. Opin. Invest. Drugs, 8: 669-681. PMID: 17668369
54. Milazzo, L., B. Menzaghi, I. Caramma, M. Nasi and O. Sangaletti et al., 2010. Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: A pilot study. AIDS, 26: 1207-1214. DOI: 10.1089/aid.2010.0024
55. Mitsuya, H., K.J. Weinhold, P.A. Furman, M. HS. Clair and S.N. Lehrman et al., 1985. 3'-Azido-3'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA., 82: 7096-7100.
56. Mondal, D., L. Pradhan, M. Ali and K.C. Agrawal, 2004. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells. Cardiovasc. Toxicol., 4: 287-302. DOI: 10.1385/CT:4:3:287
57. Ngondi, J.L., J. Oben, D.M. Forkah, L.H. Etame and D. Mbanya, 2006. The effect of different combination therapies on oxidative stress markers in hiv infected patients in cameroon. AIDS Res. Therap., 3: 19-26. DOI: 10.1186/1742-6405-3-19
58. Noor, M.A., 2007. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: Cellular mechanisms and clinical implications. Curr. HIV/AIDS Rep., 4: 126-134. DOI: 10.1007/s11904-007-0019-4
59. Opii, W.O., R. Sultana, H.M. Abdul, M. Ansari and A. Nath et al., 2007. Oxidative stress and toxicity induced by the Nucleoside Reverse Transcriptase Inhibitor (NRTI)-2: 3-dideoxycytidine (ddC): Relevance to HIV dementia. Exp. Neurol., 204: 29-38. DOI: 1016/j.expneurol.2006.09.010
60. Pallela, F., K. Delaney, A. Moorman, M. Loveless and J. Fuhrer et al., 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med., 338: 853-860. DOI: 10.1056/NEJM199803263381301
61. Pocernich, C.B., R. Sultana, H. Mohmmad-Abdul, A. Nath and A. Butterfield, 2005. HIV-dementia, Tatinduced oxidative stress and antioxidant therapeutic considerations. Brain Res. Rev., 50: 14-26. ISBN 15890409
62. Popovic, M., P.S. Sarin, M. Robert-Gurroff, V.S. Kalyanaraman and D. Mann et al., 1983. Isolation and transmission of human retrovirus (human Tcell leukemia virus). Sci., 219: 856-859. PMID: 6600519
63. Pyrko, P., A. Kardosh, W. Wang, W. Xiong and A.H. Schonthal et al., 2007. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res., 67: 10920-10928. DOI: 10.1158/0008-5472.CAN-07-0796
64. Ramamoorthy, H., B. Issac and P. Abraham, 2012. Evidence for the roles of oxidative stress, nitrosative stress and Nf-Kb activation in Tenofovir Disoproxil Fumarate (TDF) induced renal damage in rats. BMC Infect. Dis., 12: 1-6. DOI: 10.1186/1471-2334-12-S1-P6
65. Ravichandran, S., R. Veerasamy S. Raman and P.N. Krishnan and R.K. Agrawal, 2008. A overview on Hiv-1 reverse transcriptase inhibitors. Digest J. Nanomaterials Biostruct., 3: 171-187.
66. Reust, C.E., 2011. Common adverse effects of antiretroviral therapy for HIV disease. Am. Fam. Phys., 83: 1443-1451. PMID: 21671545
67. Rivero, A. and A. Jose, 2007. Mira2 and Juan A. Pineda3, Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J. Antimicrob. Chemother., 59: 342-346. DOI: 10.1093/jac/dkl524
68. Saitoh, A.T.F., C. Alvero, C.V. Fletcher and S.A. Spector, 2007. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob. Agents Chemother., 51: 4236-4242. PMID: 17893156
69. Schafer, J.J., S. Ravi, E.V. Rowland S. Ravi and N. Leon, 2011. The expanding class of non-nucleoside reverse transcriptase inhibitors for the treatment of HIV-1 infection. P T., 36: 346-364.
70. Schneider, C.D. and A.R. De Oliveira, 2004. Oxygen free radicals and exercise: Mechanisms of synthesis and adaptation to the physical training. Rev. Bras. Med. Esporte, 10: 314-318. DOI: 10.1590/S1517-86922004000400008
71. Shankar, S.S., M.P. Dube, J.C. Gorski, J.E. Klaunig and H.O. Steinberg, 2005. Indinavir impairs endothelial function in healthy HIV-negative men. Am. Heart J., 150: 933-933. PMID: 16290967
72. Shlay, J.C., G. Bartsch, G. Peng, J. Wang and C. Grunfeld et al., 2007. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J. Acquir. Immun. Defic. Syndr., 44: 506-517. DOI: 1097/QAI.0b013e31804216cf
73. Sultana, R., S. Newman, H. Mohmmad-Abdul, J.N. Keller and D.A. Butterfield, 2004. Protective effect of the xanthate, D609, on Alzheimer's amyloid betapeptide (1-42)-induced oxidative stress in primary neuronal cells. Free. Radic. Res., 38: 449-458. DOI: 10.1080/1071576021000040664
74. Sundaram, M., S. Saghayam, B. Priya, K.K. Venkatesh and P. Balakrishnan, 2008. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in Southern India. Int. J. Infect. Dis., 12: 61-66. DOI: 10.1016/j.ijid.2008.04.004
75. Suneeta, S., R. Churchill and Duncan and Y. Gilleece, 2008. Abacavir-induced hepatotoxicity: A report of two cases. AIDS, 22: 2557-2562. DOI: 1097/QAD.0b013e32831c8af4
76. Tebas, P., 2008. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: Pathogenesis, prevention and treatment options. J. Acquir. Immun. Defic. Syndr., 49: S86-92. DOI: 1097/QAI.0b013e31818651e6
77. Terry, L., E. Sprinz, R. Stein, N.B. Medeiros and J. Oliveira et al., 2006. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med. Sci. Sports. Exerc., 38: 411-417. DOI: 10.1249/01.mss.0000191347.73848.80
78. Valko, M., C.J. Rhodes, J. Moncol, M. Izakovic and M. Mazur, 2006. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact., 160: 1-40. DOI: 1016/j.cbi.2005.12.009
79. Valle, L.G.D., R.G. Hernandez and J.P. Avila, 2013. Oxidative stress associated to disease progression and toxicity during antiretroviral therapy in human immunodeficiency virus infection. J. Virol. Microbiol. DOI: 10.5171/2013.279685
80. Van Huyen, J., A. Landau, C. Piketty and M.F. Belair, 2003. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Am. J. Clin. Pathol., 119: 546-555. DOI: 10.1309/8B8BJ6AP5KGV7C1H
81. Vassimon, H.S., R. Deminice, A.A. Machado, J.P. Monteiro and A. Jordao, 2010. The association of lipodystrophy and oxidative stress biomarkers in HIV-infected men. Curr. HIV Res., 8: 364-369. DOI: 10.2174/157016210791330347
82. Wang, X., H. Chai, Q. Yao and C. Chen, 2007. Molecular mechanisms of HIV protease inhibitorinduced endothelial dysfunction. J. Acquired Immune Deficiency Syndr., 44: 493-499. DOI: 10.1097/QAI.0b013e3180322542
83. Wensing, A., N. van Maarseveen and M. Nijhuis, 2010. Fifteen years of HIV protease inhibitors: Raising the barrier to resistance. Antiviral Res., 85: 59-74. DOI: 1016/j.antiviral.2009.10.003
84. Wu, X., L. Sun, W. Zha, E. Studer and E. Gurley et al., 2010. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology, 138: 197-209. DOI: 10.1053/j.gastro.2009.08.054
85. Young, B., K. Buchacz, A. Moorman, K.C. Wood and J.T. Brooks, 2009. Renal function in patients with preexisting renal disease receiving tenofovircontaining highly active antiretroviral therapy in the HIV outpatient study. AIDS Patient Care STDS, 23: 589-592. DOI: 10.1089/apc.2008.0232
86. Yousefi, S., A. Hadadi, A. Ostovar, B.E. Noor and M. Rasoolinejad et al., 2011. Protocol of determining the effect of selenium supplementation on CD4 + T lymphocyte count in HIV/AIDS patients: A randomized double blind placebo controlled trial. Adv. Infect. Dis., 1: 20-26. DOI: 10.4236/aid.2011.12003
87. Zhou, H., E.C. Gurley, S. Jarujaron, H. Ding and Y. Fang et al., 2006. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am. J. Physiol. Gastrointestinal Liver Physiol., 291: 1071-80. PMID: 16861219